Transcriptional enhancers enable exquisite spatiotemporal control of gene expression in metazoans. 17
Introduction 34
Transcriptional enhancers were discovered as potent gene regulatory elements that act 35 independently of the distance and orientation to the target promoters 1, 2 . A broad range of 36 physiological and developmental processes rely on coordinated actions of transcriptional enhancers 37 to achieve cell type-specific and temporally-controlled gene expression 3, 4 . Numerous non-coding 38 variants associated with a variety of human traits have been observed at enhancers, implicating their 39 importance in normal physiology and disease pathogenesis [5] [6] [7] . 40
Recent studies have begun to reveal how the life cycle of enhancers progresses to induce 41 gene expression changes during development 8 . Genome-wide discovery of thousands of potential 42
, and 47 subsequent recruitment of methyltransferases KMT2C and KMT2D (aka MLL3 and MLL4, 48 respectively) leads to H3K4me1 at enhancers [14] [15] [16] . 49
Once installation of H3K4me1 "primes" enhancers, they can become either "active" or 50 "poised", depending on the acetylation or tri-methylation of H3 lysine 27 (H3K27ac or H3K27me3) 17 , 51
18
, respectively. A recent report showed that active enhancers can be negatively regulated by 52 RACK7-mediated recruitment of KDM5C, an H3K4me3/2 demethylase 19 . When genes need to be 53 turned off, e.g. pluripotency genes during differentiation of stem cell, their enhancers undergo 54 "decommissioning" by LSD1-mediated removal of the priming mark, H3K4me1 20 . Notably, "latent" 55 enhancers, i.e. DNA elements that lack TF binding or H3K4me1, can gain enhancer-like marks in 56 response to extra-cellular stimuli and promote gene expression in fully-differentiated macrophages 21 . 57
These findings highlight the dynamic H3K4 methylation of an enhancer during its life cycle. 58
Two H3K4 demethylases, LSD1 and KDM5C, have been shown to play important roles in 59 regulation of enhancers 19, 20, 22 . While KDM5C reverses H3K4me3/2 leaving H3K4me1 intact 23, 24 , 60 LSD1 can demethylate only H3K4me2/1 25 . The distinct substrate specificities raise a possibility that 61 these two H3K4 demethylases may cooperate to generate and/or maintain the balance of H3K4me 62 landscape at different classes of enhancers. For example, absence of H3K4 methylation at latent 63 enhancers could potentially be attributed to LSD1-mediated demethylation of H3K4me1. Besides the 64 decommissioning of stem cell genes and enhancers during differentiation, LSD1 has also been 65
shown to repress developmental genes 26, 27 and retrotransposons 28 in ES cells. However, it 66 remains unclear whether LSD1 and KDM5C play any role at other classes of enhancers. 67
In the present study, we demonstrate that in addition to active enhancers, LSD1 also 68 occupies poised enhancers, some of which are quickly activated (inducible enhancers) upon 69
LSD1 occupies a large fraction of primed enhancers 79
To study the role of LSD1 in regulation of enhancers and gene expression, we first examined 80 the genome-wide distribution of LSD1 at various regulatory elements. We analyzed the previously 81 published ChIP-Seq datasets of LSD1 20 , p300 29, 30 , CTCF 29, 31 , DNase-Hypersensitivity (DHS) 32 
82
and other histone modifications (see Supplementary Table 1) . p300, a histone acetyltransferase and 83 a transcriptional coactivator, has been shown to occupy both promoters and enhancers 10, 33 , 84 whereas CTCF binding sites anchor chromatin loops 34 and insulating domains [35] [36] [37] . By examining 85 the overlaps of binding sites of LSD1 (109,541, q < 0.05), p300 (86,426, q < 0.01), CTCF (58,899, p 86 < 10 -12
) and DHS sites (299,799, q < 0.05), we found that 1) a majority of p300 binding sites (70.5%, 87 Figure 1a ) were co-occupied by LSD1, 2) in contrast, only 14.7% of non-p300 CTCF-binding sites 88
were occupied by LSD1, and 3) most of the LSD1 binding sites (86%) showed an overlap (± 250 89 bases) with DHS sites. The higher degree of overlap of LSD1 with p300 compared to CTCF-only 90 sites was observed at promoter, genic, and intergenic regions (Supplementary Figure 1) . These 91 observations indicate that LSD1 occupies a large fraction of primed enhancers. 92
Next, we sought to identify regulatory elements that could potentially act as enhancers. 93
Previous studies have utilized a high H3K4me1:me3 ratio, either alone 10, 17 or in conjunction with TF 94 binding 38, 39 , DHS or binding by CBP/p300 40, 41 , to distinguish enhancers from promoters in a given 95 cell-type. H3K4me2 is observed at both promoters and enhancers and has been shown to be a 96 signature to predict enhancers 38 . We therefore included H3K4me2 data to increase the sensitivity 97 and precision of enhancer mapping. Enhancers also differ from promoters in that promoters are 98 associated with stable transcripts 42 while active enhancers are associated with expression of 99 enhancer RNA transcripts (eRNAs) [42] [43] [44] , which are short-lived due to exosome-mediated 100 degradation [44] [45] [46] . This degradation of nascent transcripts from enhancers results in a very low, albeit, 101 detectable levels of eRNAs in RNA-Seq (Figure 1b, right panel) . Global Run-On, an in vitro assay, 102
followed by high-throughput sequencing (GRO-Seq) 47 enables a sensitive and quantitative 103 evaluation of transcriptionally-engaged RNA polymerase molecules. GRO-Seq, thus, serves as an 104 indirect measure of nascent transcription at promoters and enhancers, irrespective of the 105 subsequent stability of the transcripts 42 . Therefore, we employed a high ratio of GRO-Seq:RNA-Seq 106 signals to further refine the prediction of enhancers in mESC. We focused on only intergenic 107 enhancers as we found it difficult to differentiate the eRNAs from gene-coding and promoter-108 upstream 46 transcripts. In summary, intergenic enhancers were defined as ± 500 base regions 109 around p300/DHS summits with i) H3K4me1 enrichment (rpkm ≥ 1 and ChIP:Input > 1.5), ii) 110
H3K4me3 lower than either H3K4me1 or H3K4me2, iii) a low rate of transcription (RNA-Seq fpkm < 111 0.5), iv) a GRO-Seq:RNA-Seq ratio > 5, and v) a high average mappability to exclude repetitive 112 regions. This pipeline predicted a total of 22,047 intergenic enhancers in mESC (Supplementary 113 Table 2 ). 114 LSD1 has been shown to occupy enhancers in various cell types 20, 48, 49 . However, the 115 genome-wide relationship between LSD1 binding and chromatin states at enhancers, such as 116 histone-modification landscapes and eRNA transcription, remains unclear. To address this issue, we 117 first subdivided the 22,047 predicted intergenic enhancers into quartiles (Q1-Q4, Figure 1b) based 118 on the enrichment of H3K4me2 relative to H3K4me1. Similar to a previous observation in K562 cells 119
42
, we noted a positive correlation between eRNA levels, measured by GRO-Seq, Nuclear RNA-Seq 120 or RNA-Seq, and H3K4me2 levels (Figure 1b) . Acetylations of H3K9 and H3K27 and eRNA 121 expression have been established as signatures of active enhancers 9, 17, 18 . Consistently, we also 122 observed that enhancers with higher transcription levels displayed higher acetylation levels of H3K9 123 and H3K27 relative to trimethylation (Supplementary Figure 2) . 124
We then determined the extent of LSD1 binding across various enhancer classes and found 125 that a large fraction (63.2%) of the predicted 22,047 enhancers is bound by LSD1 (Figure 1c) . 126 Surprisingly, we found that LSD1 occupancy at enhancers increased with increasing levels of 127
H3K4me2 or increasing levels of GRO-Seq signals (Supplementary Figures 3 and 4a) . We then 128 calculated the correlation coefficients between LSD1 levels and levels of various histone 129 modifications at promoter distal regions, i.e. excluding TSS ± 1500 bases. Compared to H3K4me1 (r 130 = 0.5745) and H3K4me3 (r = 0.486), we found that LSD1 levels showed the highest correlations with 131 its primary substrate, H3K4me2 (r = 0.627, Supplementary Figure 4b) , and H3K27ac (r = 0.604), a 132 marker for enhancer activity. In contrast, H3K27me3 and H3K9me3 were inversely correlated with 133 LSD1 levels (Supplementary Figure 4b) . We also classified 22,047 intergenic enhancers into poised, 134 active, and intermediate enhancers based on their H3K27me3 and H3K27ac levels, according to the 135 previous report 18 . We found that LSD1 occupies substantial fractions of each of the three enhancer 136 classes with increased occupancy of active enhancers compared to other classes (Figure 1d) . 137
Similar patterns were observed when we used the levels of H3K9me3 and H3K9ac to classify 138 enhancers as described previously 41 ( Figure 1e ). These results indicate that LSD1 binds to multiple 139 enhancer classes with positive correlations to H3K4me2, H3K27/K9 acetylation and eRNA levels. 140
141
LSD1 rarely binds to cell-type specific "latent" enhancers 142
Higher LSD1 occupancy at more active enhancers may contradict with the LSD1's classical 143 role as a transcriptional repressor of neuron-specific genes in non-neuronal tissues 25, 50 .
RE1-144
Silencing Transcription factor (REST) is known to be expressed in non-neuronal cells with the role of 145 repression of neuronal genes in these cell-types through the Corepressor of REST(CoREST) 146 complex 50 . We analyzed the previously published REST ChIP-Seq dataset 20 and found that only 147 1.31% of predicted enhancers (288 out of 22,047) were bound by REST in mESC. However, a 148 majority (91%) of these REST-positive enhancers were bound by LSD1. These data suggest that 149 REST/LSD1-mediated suppression is not the primary mechanism of enhancer regulation in mESC. 150
Enhancers that are inert, free of TFs, and thus, insensitive to DNase I, are referred to as "latent" 151 enhancers in a given cell type 21 . The low occupancy of primed enhancers by REST/LSD1 prompted 152 us to test if LSD1 contributes to regulation of latent enhancers. We first looked at the mir290 cluster, 153 which is specifically expressed in mESC and early developmental stages 51 . In mESC, several 154 enhancers upstream of its promoter, show high DHS, p300 binding and high GRO-Seq signals 155 accompanied with strong LSD1 binding events (Figure 2a ). These mir290 enhancers lack brain-156 derived DHS, GRO-Seq signal and H3K4 methylation in cortical neurons (CN), demonstrating that 157 these enhancers are primed in mESC but are latent in CN. LSD1 ChIP-Seq data from neural stem 158 cells (NSC) 52 , however, showed a lack of LSD1 binding at these latent enhancers. Conversely, two 159 enhancers upstream of Npas4 (marked with asterisks, Figure 2b ), a gene predominantly expressed 160 in the brain, showed brain-specific DHS and LSD1 occupancy, GRO-Seq signals and high H3K4me1, 161 specifically in the neuronal cell types (NSC or CN). In mESC, LSD1 is absent at these brain-specific 162 DHS sites upstream of the Npas4 promoter (Figure 2b ). These two examples suggest that LSD1 163 could primarily be recruited to primed enhancers in a given tissue in a TF-binding dependent manner. 164
To ascertain this specificity of LSD1 recruitment to primed enhancers on a genome-wide 165 scale, we sought to identify genomic elements that are latent in mESC but are primed in other cell 166 types. We identified DHS sites from mESC (398,675, q < 0.01) and four additional mouse tissues, 167 including adult brain (415,400), heart (320,416), liver (207,046), and lung (358,575), using Hotspot 168 (v4.1) 53 . Similar to our earlier observation ( Supplementary Figure 1) , we found that most of mESC 169 LSD1-binding sites (86%) overlapped with mESC hotspots (Figure 2c ). Next, we performed an 170 intersection of hotspots from the five tissues. This resulted in tens of thousands of hotspots, which 171 could potentially act as tissue-specific enhancers in a given tissue and latent in others (Figure 2d, e) . 172
Motif analysis on promoter-distal hotspots revealed that these tissue-specific hotspots are indeed 173 enriched with binding sites for lineage-specific TFs (Supplementary Figure 5) . In agreement with the 174 mir290 and Npas4 loci, mESC LSD1 binding sites showed negligible overlaps with tissue-specific 175 hotspots (0.40-0.69%), whereas 14.31% of mESC-specific hotspots were bound by LSD1 (Figure 2d , 176 e). Based on these data, we concluded that LSD1 is predominantly recruited to primed enhancers 177 and is not actively involved in maintaining inactivity of latent enhancers in mESC. . Alternatively, the positive correlation may reflect a negative 186 feedback mechanism, in which LSD1 searches for and binds to genomic regions with high H3K4me2 187 levels and reverses this modification to regulate optimal enhancer activity. 188
To test whether LSD1 is involved in maintaining precise levels of H3K4 methylation at 189 enhancers, we investigated the previously generated mESC line that lacks LSD1 due to the insertion 190 of a gene-trap cassette (Lsd1-GT) 28 . Western blot analysis of mESC carrying either wild-type (WT) 191
Lsd1 or Lsd1-GT did not show any detectable differences in total H3K4me1, H3K4me2, H3K4me3 or 192
H3K27ac levels (Supplementary Figure 6) . We then performed ChIP-Seq to measure H3K4me 193 levels across the genomes of these two mESC lines. Since LSD1 is known to associate with multiple 194 HDAC-containing co-repressor complexes, including the CoREST 50, 58 and NuRD 59 complexes, we 195 also included H3K27ac and HDAC1 in our ChIP-Seq analysis. 196
Genome-wide localization analysis (ChIP-Seq) profiles, which reflect the spatial distribution of 197 these marks, looked highly similar between the two genotypes at most of the loci. Upon the loss of 198 LSD1, however, H3K4 methylations displayed statistically-significant increases at active, poised, and 199 intermediate LSD1-target enhancers, which were accompanied with conspicuous increases in 200 H3K27ac (Figure 3a, Supplementary Figure 7a) . Similar changes were also observed at enhancers 201 that showed a significant increase in eRNA expression (see next section) in the Lsd1-GT mESC 202 (Supplementary Figure 7) . Interestingly, HDAC1 levels did not change significantly at poised 203 enhancers, while active or poised enhancers showed a small but significant increase in HDAC1 204 binding (Figure 3a) , which could be attributed to either experimental variations or unknown 205 mechanisms to compensate for the loss of LSD1. The inability of HDAC1 to remove H3K27ac in 206
Lsd1-GT cells is consistent with the previous observations that HDAC activity is negatively 207 influenced by the presence of H3K4me 27, 60 . Representative genes Pou5f1 (Figure 3b ) and Cbln4 208 (Figure 3c ), which are normally active or poised in undifferentiated mESC, respectively, showed 209 relatively higher H3K4me and H3K27ac at both promoters and enhancers in Lsd1-GT mESC. We 210 also observed a concomitant increase in both promoter-and enhancer-associated GRO-Seq signals 211 at these loci in Lsd1-GT mESC (Figure 3b LSD1 or KDM5C and 52.1% of total were bound by both (Figure 4a) . 228
We generated Kdm5c-knockout (KO) mESC by transfecting a Cre-expression plasmid into 229 the mESC harboring the floxed exons 11 and 12, which encode the catalytic JmjC domain 61, 62 , and 230 confirmed the loss of KDM5C (Supplementary Figure 8) . We then asked if the loss of either LSD1 or 231 KDM5C leads to aberrant enhancer activity by quantifying changes in GRO-Seq signals at 232 enhancers. To identify misregulated enhancers, we calculated the number of GRO-Seq reads 233 mapping within ± 500 bases of the center of the predicted enhancers and normalized them against 234 199,209 p300/DHS sites across the whole genome using DESeq
63
. Upon the loss of LSD1, a large 235 fraction (24.8%, 5,471) of total intergenic enhancers showed a significant elevation in associated 236 GRO-Seq transcripts, while a small number 674 (3.06%) displayed a reduced activity with a stringent 237 cutoff of q < 0.05 ( Figure 4b ). Next, we tested if this elevation of GRO-Seq signals is specific to 238 poised, intermediate or active enhancers. We found that all three enhancer classes showed a 239 significant increase in associated nascent transcripts (p < 2.2e-16, Wilcoxon signed-rank test, Figure  240 4c), indicating that LSD1 is required for genome-wide suppression of aberrant enhancer activities. 241
Using the same DESeq cutoff, however, we were not able to identify any misregulated 242 enhancers in Kdm5c-KO mESC. After relaxing the cutoff to p < 0.05, we could identify only 63 243 upregulated and 102 downregulated enhancers upon the loss of KDM5C (Figure 4d ). To confirm that 244 these observations were not dependent on differences in sequencing depths or inter-replicate 245 variability, equal number of reads were randomly selected from each GRO-Seq sample and pairwise 246
DESeq comparisons between individual replicates of either genotypes were repeated. Thus, in 247 contrast to the crucial role of LSD1, KDM5C is largely dispensable for enhancer suppression in 248
mESC. 249
Since GRO-Seq is an in vitro transcription assay, we sought to validate this global 250 upregulation of enhancers upon LSD1 depletion in mESC under physiological conditions by 251 sequencing total cellular RNAs (RNA-Seq) and nuclear RNAs (Nuclear RNA-Seq). Either RNA-Seq 252 or Nuclear RNA-Seq could not provide sufficiently high eRNA signals to call differentially-expressed 253 enhancers likely due to the aforementioned exosome-mediated degradation of eRNAs. However, 254 when we evaluated eRNA levels at all the intergenic enhancers as a group, RNA-Seq and Nuclear 255 Figure 9 ). These data demonstrate 256 that LSD1, but not KDM5C, is required for suppression of aberrant enhancer activities in mESC. 257
RNA-Seq corroborated our GRO-Seq results (Supplementary

Aberrant changes in enhancer activity are associated with misregulation of physically-259 interacting genes 260
The standard approach to gauge the influence of enhancer misregulation on gene 261 expression has been to quantify changes in expression of genes that are located in proximity to the 262 enhancers of interest. However, recent advances in genome-wide profiling of chromatin interactions 263 64-66 have paved the way for a more precise determination of enhancer-promoter interactions. To 264 identify genes that physically interact with our set of predicted enhancers, we utilized the recently-265 published "HiCap" data set, which is a high-resolution map of promoter-anchored chromatin 266 interactions in mESC Figure 10c) . 284
Additionally, when interacting genes were called on the basis of genomic proximity to the enhancers, 285
we observed a similar trend (Supplementary Figure 11) . These results indicate that LSD1's role at 286 enhancers is important for a precise transcription of their cognate genes. 287
To further corroborate if LSD1 and its catalytic activity are required for suppression of 288 enhancer activity and associated genes, we utilized luciferase reporter assays in Lsd1-GT mESC. 289
We selected 11 enhancers with two latent enhancers and at least one enhancer from each of poised, 290 intermediate, and active enhancers that showed significant upregulation in Lsd1-GT mESC 291 compared to WT-mESC and also showed an upregulation of the associated gene. 1.0 ~ 1.2 kb of the 292 enhancer-containing regions were cloned downstream of the HSV-Thymidine Kinase promoter-293 driven firefly luciferase gene. Lsd1-GT mESC were transfected with a control plasmid or plasmids 294 expressing either human LSD1 or the catalytically inactive LSD1-K661A mutant 68 along with the 295 reporter plasmids. We found that LSD1's catalytic activity is indeed required for suppression of all 296 the active enhancers tested (p < 0.1, Student's t-tests, Supplementary Figure 12) , consistent with 297 high levels of LSD1 at these enhancers in mESC. In contrast, one of the Nanog enhancers, which 298 had not displayed a change upon the loss of LSD1 in mESC, was unaffected by LSD1 expression. 299
We observed lower enhancer activities of the latent, poised, and intermediate enhancers compared 300 to the active enhancers, indicating that our enhancer classification could accurately predict enhancer 301 activity. However, we found it difficult to interpret the effect of LSD1 or its catalytic activity at these 302 weak enhancers as they failed to enhance the activity of the promoter. The study found that only the enhancers that displayed activity dependent changes in H3K27ac 367
were involved in promoting ARG transcription 76 . Next, we investigated if the premature upregulation 368 of ARGs in Lsd1-KD neurons was accompanied with misregulation of any of these activity-regulated 369 enhancer groups. Analysis of BrU-Seq data revealed that loss of LSD1 did not have a significant 370 impact on enhancers that do not display any activity-dependent changes in H3K27ac (Wilcoxon 371 signed-ranked test, Figure 7d ). However, Lsd1-KD led to a significant upregulation of eRNA levels at 372 the enhancers that gain or lose H3K27ac upon KCl treatment (Figure 7d, Supplementary Figure 14a) . 373
Interestingly, the group of enhancers with no H3K27ac either before or after depolarization, and are 374 presumably poised neuronal enhancers, also showed an upregulation upon the loss of LSD1 (Figure  375 7d, Supplementary Figure 14a ). Similar to our earlier observations with RNA-Seq and Nuclear RNA-376
Seq in mESC, the eRNA signals with BrU-Seq were considerably lower than those with mESC GRO-377
Seq to obtain sufficiently-high statistical power for comparison; therefore, we aggregated eRNA 378 signals from the two control and the two Lsd1-KD experimental groups for this analysis (Figure 7d , 379 Supplementary Figure 14a) . Similar trends were observed in analysis without grouping the samples 380 (Supplementary Figure 14b) . These data indicate that LSD1 is required for genome-wide 381 suppression of premature enhancer activation in resting neurons. enhancers are destined to be either "active" or "poised" (Supplementary Figure 15) . LSD1 then 420 counteracts with MLL3/4 to maintain an optimal H3K4me levels. Enhancers with a relatively low 421
H3K4me2 may represent early stages of priming by TFs and MLLs. It is possible that enhancers with 422 low levels of H3K4me2 recruit little LSD1, which is not detectable by ChIP-Seq (Q1, Figure 1b) . 423
When gene expression needs to be increased, recruitment of additional factors and/or MLL3/4 may 424 convert these less active enhancers to more active enhancers with higher H3K4 methylation and 425
H3K27ac, which would then require higher levels of LSD1. LSD1's recruitment might also serve as a 426 surveillance mechanism to suppress ectopic installation of H3K4 methylation and spurious activation 427 of enhancers. 428
During differentiation of mES cells, the pluripotency enhancers may be unprimed by the loss 429 of ES-specific TFs followed by the loss of MLL3/4 and H3K4 methylation. Our model is not mutually 430 exclusive to LSD1-mediated decommissioning of enhancers, as LSD1 could remove remnant 431
H3K4me2/me1 to completely disengage the enhancer from active regulation. To further elucidate the 432 mechanisms of decommissioning of pluripotency enhancers, it will be important to determine how 433 early differentiation cues shift the balance of MLL3/4-mediated H3K4 methylation and LSD1-434 mediated demethylation. 435
Enrichment of H3K4me1 and depletion of H3K4me3 was the first combination of chromatin 436
signatures to predict a large number of transcriptional enhancers in a mammalian genome 10, 11 . 437
More recent studies have shown H3K4me3 to be present at a subset of active enhancers 83 with a 438 positive correlation between the H3K4me3/me1 ratio and enhancer transcription levels 42 . We found 439 that KDM5C and LSD1 can co-occupy enhancers in mES cells (Figure 4a) . However, only the loss of 440 LSD1, but not KDM5C, displayed significant changes in enhancer activity and gene expression, 441
highlighting an essential and non-redundant role of LSD1 in mES cells. KDM5C has been implicated 442 in both promotion of enhancer activity by generating H3K4me1 in mES cells 22 , and suppression of 443 over-activation of enhancers in breast cancer cells 19 . Consistent with the former study, our analysis 444 found a small reduction in eRNA levels in Kdm5c-KO mESC (Supplementary Figure 9) . In addition to 445 Kdm5c, other KDM5 family members, Kdm5a and Kdm5b, are also expressed in mES cells at similar 446 .
Since our 463
RNAi approach depleted both neuroLSD1 and canonical LSD1 in CN, it remains unclear if one or 464 both of LSD1 isoforms mediate the suppression of activity-regulated enhancers and ARGs. Given 465 that the genetic ablation of neuroLSD1 led to a downregulation of ARG expression 49, 91 , it is more 466 likely that the canonical LSD1, and not neuroLSD1, is involved in the suppression of activity-467 regulated enhancers. Loss-of-function LSD1/KDM1A mutations have been genetically associated 468 with several neurodevelopmental conditions [92] [93] [94] . These disorders could possibly be attributed to 469 uncontrolled activation of activity-regulated genes and enhancers upon the loss of LSD1 and/or 470 neuroLSD1. LSD1-mediated homeostasis of transcriptional enhancers, therefore, underlies various 471 physiological processes including embryonic development and human cognitive function. 472
Methods 474
See supplementary methods for details. 475
Cell culture 476
Lsd1-WT and Lsd1-GT mESC have been described previously 28 . Kdm5c-KO mESC were 477 derived from the previously described mESC that carry the floxed Kdm5c allele 75 by Cre-mediated 478 deletion of exons 11 and 12, which encode the enzymatic JmjC domain. mESC were grown on 479 gelatin coated plates. 480
Western blot analysis 481
mESC or CN were lysed in Laemmli sample buffer, sonicated, and subjected to SDS-PAGE. 482
Western blot analyses were carried out using standard protocols using anti-H3K4me1 (ab8895, RNA, nuclei were isolated as described previously 98 with minor modifications. Libraries from rRNA-501 depleted RNA were prepared using Direct Ligation of Adapters to First-strand cDNA (DLAF) 97 . 502
Global Run-On 503
GRO was modified from the method described previously 47, 98 . In addition to the presence of 504 0.2% IGEPAL CA-630, GRO on Kdm5c mESC, Lsd1 mESC and CN were done in presence of 0.5%, 505 0.25% and 0.2% of N-Lauroylsarcosine, respectively for 8 min at 30C. 506
BrU-Seq 507
Cortical neurons (DIV 11), after shRNA treatment for four days, were incubated with 2 mM 5-508
Bromouridine (850187, Sigma) for 32 min at 37C. To reduce the number of steps for library 509 preparation, we developed Direct Ligation of Adaptor to the 3' end of RNA (DLAR), a method 510 suitable for preparation of libraries for BrU-Seq. 511
All sequencing experiments were conducted in biological duplicates concurrently with 512 different genotypes to minimize technical variations. 513
Sequencing and Alignment 514
Multiplexed libraries were subjected to single-end sequencing on Illumina HiSeq 2000/2500 515 instruments using standard oligonucleotides designed for multiplexed paired-end sequencing, except 516 that BrU-Seq indices were sequenced with DLAR_Index_Read:5'-517 CATAGGAAGAGCACACGTCTGAACTCCAGTCAC-3'. ChIP-Seq reads were mapped to the mm9 518 genome using Bowtie1 (v1.1.2) 99 allowing for up to two mismatches. PCR duplicates from ChIP-Seq 519 reads were removed using samtools rmdup utility (v1.3) 100 and coverage along the genome was 520 calculated using BEDTools (v2.25.0) 101 after extending the ChIP-Seq reads to a total length of 180 521 bases. RNA-Seq libraries were mapped to the mm9 genome and transcriptome using TopHat2 522 (v2.1.0) 102 with Bowtie2 (v2.2.6)
103
. For GRO-Seq and BrU-Seq, full length reads were first aligned 523 using Bowtie1 or Tophat2, respectively. Adaptor sequences were trimmed from the unmapped reads 524 using BBDuk utility 104 and reads were remapped and merged to the reads from the initial alignment. 525
Only uniquely mapping reads were retained for further analysis and libraries were normalized to total 526 number of non-mitochondrial and non-ribosomal reads. 527
Analysis 528
MACS2 (v 2.1.0) 105 was used to call DHS or ChIP-Seq peaks. For selection of candidate 529 p300/DHS sites for enhancer prediction, we first scanned the genome for the strongest (with highest 530 MACS2 signal) p300 or DHS site in a 1,250 base sliding window. When both p300 and DHS sites 531 were present in the same window, p300 binding site was given higher precedence over any DHS 532 sites. Intergenic p300/DHS sites were defined as sites that were outside of 1.25 kbp upstream to 3 533 kbp downstream of the genes. LSD1 has been shown to be involved in silencing of repetitive 534 elements including endogenous retroviral elements (ERVs) 28 . Therefore, to focus on prototypical 535 enhancers in this study, we excluded p300/DHS sites with a low mappability (M 1 < 0.75 and M 2 < 536 0.75), where M 1 and M 2 indicate the fraction of uniquely mapping bases 106 within ± 500 and ± 100 537 bases, respectively, of the p300/DHS site. p300/DHS sites within the ENCODE blacklisted regions 5 538 were also excluded. 539 Volcano plots of changes in mRNA levels (RNA-Seq) of genes that physically interact with misregulated enhancers. Based on changes in enhancer-associated GRO-Seq signals upon the loss of LSD1, enhancers were subdivided as significantly up (q < 0.05, DESeq), significantly down, moderately up (0.05 ≤ q < 0.25), moderately down, and the rest. When multiple enhancers showed interactions with a single promoter, assignment of the genes to each enhancer subgroup was prioritized in the aforementioned order. Total number of associated genes (n) and p-values (p) from Wilcoxon signed-rank tests on differences between mRNA levels in Lsd1-GT and WT mESC are shown beneath each panel. Note that more genes anchored to upregulated enhancers are upregulated compared to genes that interact with downregulated enhancers. . (b, c) Scatter plots of mRNA levels (b) and levels of nascent transcription (c), as measured by RNA-Seq and GRO-Seq, respectively in WT and Lsd1-GT mESC. Number (n) of significantly-upregulated (q < 0.05) and -downregulated genes in each category are shown in blue and orange, respectively. Upon the loss of LSD1 in mESC, both groups of "induced" and "decommissioned" genes show a significant increase (p < 2.2e-16, Wilcoxon signed-rank test) in mRNA levels and nascent transcription. 
